Before prescribing Saxenda^® (liraglutide (rys) 6 mg/mL) as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index of ≥ 30 kg/m² (obese) or ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight related comorbidity, such as dysglycaemia (pre-diabetes and type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea, please review the full datasheet for information on dosage, contraindications, precautions, interactions and adverse events available at www.medsafe.govt.nz. Saxenda^® (liraglutide (rys) 6 mg/mL) an unfunded Prescription Medicine - a prescription charge and doctor´s fees will apply.

Before prescribing Victoza^® (liraglutide (rys) 6 mg/mL) a Prescription Medicine for glycaemic control in type 2 diabetes as a adjunct to diet and exercise, please review the full datasheet for information on dosage, contraindications, precautions, interactions and adverse events available at www.medsafe.govt.nz. Victoza^® is a fully funded medicine – special authority criteria apply.